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Abstract
Purpose: Diabetic retinopathy is a leading cause of vision loss. There is a great need for early diagnosis prior 
to the occurrence of irreversible structural damages. Expression of endothelial adhesion molecules is observed 
before the onset of diabetic vascular damage; however, to date, these molecules cannot be visualized in vivo.
Methods: To quantify the expression of endothelial surface molecules, we generated imaging probes that 
bind to ICAM‑1. The α‑ICAM‑1 probes were characterized via flow cytometry under microfluidic conditions. 
Probes were systemically injected into normal and diabetic rats, and their adhesion in the retinal microvessels 
was visualized via confocal scanning laser ophthalmoscopy. Histology was performed to validate in vivo 
imaging results. Vascular pathologies were visualized using trypsin‑digested retinal preparations.
Results: The α‑ICAM‑1 probes showed significantly higher adhesion to retinal microvessels in diabetic 
rats than in normal controls (P < 0.01), whereas binding of control probes did not differ between the two 
groups. Western blotting results showed higher ICAM‑1 expression in retinas of T1D animals than in normal 
controls. Retinal endothelial ICAM‑1 expression was observed via molecular imaging before markers of 
structural damage, such as pericyte ghosts and acellular capillaries.
Conclusion: Results indicate that molecular imaging can be used to detect subtle changes in the diabetic retina 
prior to the occurrence of irreversible pathology. Thus, ICAM‑1 could serve as a diagnostic target in patients with 
diabetes. This study provides a proof of principle for non‑invasive subclinical diagnosis in experimental diabetic 
retinopathy. Further development of this technology could improve management of diabetic complications.
Keywords: Biomarkers; Diabetic Retinopathy; Early Diagnosis; ICAM‑1
Correspondence to: 
Ali Hafezi‑Moghadam, MD, PhD. 
Brigham Women’s Hospital, Molecular Biomarkers 
Nano‑Imaging Laboratory (MBNI), 75 Francis St., TH315, 
Boston, Massachusetts 02115, USA. 
E‑mail: ahm@bwh.harvard.edu
Received: 06‑12‑2016 Accepted: 15‑02‑2017
INTRODUCTION
The prevalence of diabetes is rapidly increasing 
worldwide.[1] The vascular complications of diabetes, 
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which develop over many years, are the major causes of 
morbidity and mortality. A microvascular manifestation 
of diabetes is diabetic retinopathy (DR), a leading cause 
of vision loss.[2] Detection during the subclinical period 
leads to a higher chance of the prevention of disease 
progression to the clinical stage.[3] An urgent need thus 
exists to develop strategies to diagnose DR prior to the 
occurrence of structural damage.
Retinal vessels can be visualized through non‑invasive 
means, such as funduscopy, angiography, and optical 
coherence tomography (OCT); thus, in the past decades, 
several studies have attempted to identify early changes 
serving as predictors of retinopathy,[3] focusing on 
morphological characteristics, such as retinal vascular 
dimensions or functional characteristics, including 
blood flow rate, oxygenation, or leakage of systemically 
applied dyes, such as those used in fluorescein 
angiography.[3] However, an effective biomarker for 
DR was not  successfully  identified.[3] Indeed, results 
of the Wisconsin Epidemiologic Study of Diabetic 
Retinopathy (WESDR)[4] and the New Jersey 725 study 
revealed no correlation between retinal vascular caliber 
and the risk of DR.[5] It is uncertain whether continued 
use of the existing architectural and functional vascular 
measurements with more rigor would provide a reliable 
biomarker for early diagnosis of DR.
Therefore, we have chosen a categorically different 
strategy to visualize molecular biomarkers for DR. 
The current requirement for a biomarker is objective 
measurement as an indicator of pathogenic processes.[3] 
For effective and timely prevention of retinopathy, a 
biomarker should be non‑invasively detectable in the 
early subclinical disease stage, such as in the period 
before capillaries obliterate. Furthermore, the ideal 
biomarker should be causally linked to retinal pathology 
development.[6]
In diabetes, the microvascular endothelium is 
known to express ICAM‑1.[7,8] Endothelial ICAM‑1 
binds to leukocyte β2 integrins and results in leukocyte 
accumulation in retinal microvessels. Binding of the β2 
integrins to the endothelial ICAM‑1 in experimental DR 
subsequently leads to opening of the blood retinal barrier 
and leakage.[9] Our current approach is to target retinal 
endothelial ICAM‑1 as an indicator of early pathology.
We introduce a new imaging technique capable of 
detecting single molecules in the retina.[10] This was 
accomplished by generating imaging probes targeting 
specific endothelial surface molecules;[10‑13] once in 
circulation, the probes interact with their targets, located 
on the intra‑luminal vessel surfaces.[13] The binding 
interactions are then visualized using light‑based 
imaging,[10,11] which provides quantitative, highly 
sensitive and specific expression and localization 
information for the targets.[10] Using this approach, we 
have previously shown that VEGFR‑2 is upregulated 
in the retinal vessels of diabetic animals.[14] The non‑
invasive nature of the described imaging approach can 
be further applied in longitudinal investigations, which 
is not highly feasible using currently existing endpoint 
techniques.[15]
Considering that leukocyte adhesion in retinal vessels 
precedes structural damage in DR,[16] we hypothesized 
that mimicking immune cell recruitment using our 
custom‑designed imaging probes can reveal the earliest 
signs of DR. In this study, we evaluated endothelial 
ICAM‑1 in normal and diabetic animals as a potential 
indicator for endothelial injury.
METHODS
Streptozotocin‑induced Diabetes
All experiments were performed in accordance 
with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. Male Long‑Evans rats 
(180–200 g, six to seven weeks old) were obtained from 
Charles River Laboratory (Wilmington, MA). After 16 h 
of overnight fasting, diabetes was induced in each animal 
via intraperitoneal injection of 12 mg of streptozotocin 
(STZ, minimum 98%, HPLC, Sigma‑Aldrich, St. Louis, 
MO) diluted in 0.2 ml of citrate buffer (0.1 M, pH = 4.5). 
Control animals received an intraperitoneal injection 
of vehicle (citrate buffer). Animals with blood glucose 
levels greater than 250 mg/dl at 24 h after STZ injection 
were considered diabetic. Body weights and blood 
glucose levels were regularly measured. Animals were 
maintained in an air‑conditioned room under a 12‑h 
light/dark cycle and were given free access to water 
and food.
Preparation of the Molecular Imaging Probes
Carboxylated microspheres (MS, 1 and 2 μm, Polysciences, 
Inc.; Warrington, PA) were covalently conjugated to 
Protein G as previously described.[14] Conjugated probes 
were then incubated with anti‑Intercellular‑Adhesion 
Molecule‑1 (α‑ICAM‑1 mAb, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA) or human IgG (hIgG, ZYMED 
Laboratories, Carlsbad, CA) for 2 hours at room 
temperature (approximately 22 degrees Celsius) on 
a rotary shaker. Probes were then washed with PBS 
containing 0.1% BSA.
Interaction and Accumulation of the Molecular 
Imaging Probes In vivo
To evaluate the adhesion of the imaging probes 
under physiological flow conditions  in  the  rat  retina 
during diabetes, high‑resolution images of the fundus 
were captured continuously using a scanning laser 
ophthalmoscope (SLO; HRA2; Heidelberg Engineering, 
Dossenheim, Germany) coupled with a computer‑assisted 
image analysis system.
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Rats were anesthetized with xylazine hydrochloride 
(10 mg/kg) and ketamine hydrochloride (50 mg/kg). 
Pupils were dilated with 0.5% tropicamide and 2.5% 
phenylephrine hydrochloride. A contact lens was used 
to retain corneal clarity throughout the experiment. 
Probes were injected into the femoral vein. Thereafter, 
animals were placed on a platform in front of the SLO. 
Movement of the probes through the vessels and their 
interactions with the endothelium were captured in 
fluorescent mode. An argon blue  laser with a  regular 
emission filter for fluorescein angiography was used as 
the illumination source, because the spectral properties 
of the imaging probes are similar to those of sodium 
fluorescein. Images were obtained at a 30º angle at a rate 
of 15 frames per second and recorded on a computer for 
further analysis. Videos were obtained for 10 minutes 
after probe injections. The number of accumulated 
probes in the retina was quantified as distinct stationary 
fluorescent marks with very high contrast against 
the non‑fluorescent  background.[10‑12] The number of 
the interacting probes were counted using Image J 
software (1.41o, Java 1.60_15; NIH).[17]
Ex vivo Evaluation of the Accumulation of the 
Imaging Probes
To directly visualize the interactions between the imaging 
probes and the retinal endothelium, retinal flatmounts 
were prepared. Rats were perfused 30 minutes after probe 
injection with PBS and rhodamine‑labeled concanavalin 
A lectin (ConA, Vector Laboratories, Burlingame, CA). 
For upper body perfusion, the chest cavity was opened; 
the vena cava inferior and the abdominal aorta were 
clamped, after which a 24‑gauge needle was inserted 
from the apex of the left ventricle into the aorta. Drainage 
was achieved by opening the right atrium. Animals were 
perfused with 30 ml PBS to wash out intravascular content 
and unbound probes, followed by washing with 0.15 ml 
of ConA in 15 ml of PBS to stain the vascular endothelium 
and firmly adhering  leukocytes and again with 15 ml 
of PBS to remove the excess ConA. Immediately after 
perfusion, eyes were enucleated, and the retinas were 
microdissected and flatmounted using a fluorescence 
anti‑fading medium (Vectashield, Vector Laboratories, 
Burlingame, CA). Tissues were then observed under 
an epifluorescence microscope (DM RXA; Leica, 
Deerfield,  IL) with both an FITC‑  (excitation,  488 nm; 
detection, 505–530 nm) and a rhodamine filter (excitation, 
543 nm; detection, >560 nm). Images were acquired 
using a high‑sensitivity digital camera connected to 
a computer‑assisted image analysis system. Openlab 
image analysis software (Improvision, Boston, MA) was 
used to merge images of the probes (green) with those 
of the retinal vessels (red). The number of probes was 
counted using Image J software. In each preparation, 
micrographs (10×) from five different fields of view (optic 
disc, nasally, temporally, superiorly, and inferiorly) were 
obtained, and the number of probes were counted and 
averaged.
Flow Cytometry
The average number of α‑ICAM‑1 mAbs on the surfaces 
of the imaging probes was determined using flow 
cytometry. Non‑fluorescent microspheres (Polysciences, 
Inc., Warrington, PA) conjugated to α‑ICAM or IgG were 
incubated with either FITC conjugated goat‑α‑mouse Ab 
or its isotype control. Microspheres were centrifuged, 
washed twice, and resuspended in PBS. The fluorescence 
intensities of the microspheres were measured using a 
FACScan (Coulter EPICS XL) equipped with the ‘System 
Work II’ software.
To quantify the number of copies of the molecules 
conjugated on the surface of the microspheres, mean 
fluorescence Intensity (MFI) was plotted against a 
calibration curve constructed as previously described.[11]
Adhesion of  the Imaging Probes to 
Immobilized ICAM‑1 Under Flow Conditions
Adhesion properties of the conjugated probes were 
examined using the micro flow chamber assay.[18] Glass 
microchambers were coated with recombinant rat 
ICAM‑1 (5 μg/ml; R and D, 583‑IC‑050) at 4°C overnight. 
The next day, the ICAM‑1‑coated microfluidic chambers 
were connected to biocompatible polyester tubings 
(Small Parts Inc. #TGY‑010‑C) and a 1‑ml syringe filled 
with α‑ICAM‑1 probes or control probes (1:200 dilution 
compared to animal experiments). A syringe pump 
injected α‑ICAM‑1 or human IgG‑conjugated probes 
into  the flow  chambers  at  2 dynes/cm2 shear stress, 
which were prepared as previously described.[19] Video 
microscopic images of the flow through the chambers 
were obtained for further analysis.
Western Blotting
Animals were perfused with PBS and eyes subsequently 
enucleated. The retina was carefully isolated and 
placed in 100 μl of lysis buffer (mammalian cell 
lysis kit MCL 1, Sigma Chemical Co, St. Louis, MO) 
supplemented with protease inhibitors and phosphatase 
inhibitors (Sigma) and then sonicated. The lysate 
was centrifuged, and the supernatant was collected. 
Samples containing equal amounts of total protein 
were separated via SDS‑PAGE (sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis) and 
electro‑blotted  onto PVDF  (polyvinylidene fluoride) 
membranes (Life Technologies, Carlsbad, CA). 
Non‑specific binding was blocked with 5% skim 
milk. Afterwards, membranes were incubated with a 
rabbit anti ICAM‑1 polyclonal antibody (1:200 Santa 
Cruz Biotechnology, Santa Cruz, CA) or an anti 
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β‑tubulin mAb (1:2000; Abcam, Cambridge, MA) at 4°C 
overnight, followed by incubation with horseradish 
peroxidase‑conjugated donkey or sheep anti rabbit 
or mouse IgG (1:2000; GE Healthcare UK limited 
Buckinghamshire, UK). Signals were visualized based on 
chemiluminescence (ECL kit; GE Healthcare UK limited, 
Buckinghamshire, UK) according to the manufacturer’s 
protocol.
Trypsin Digestion and Analysis of Retinal 
Vasculature
Trypsin digestion of retinal vessels is the standard 
technique currently used to detect structural pathologies 
in diabetes.[19] The eyes of normal and diabetic rats 
were enucleated and fixed in 10% neutral buffered 
formalin. Eyes were placed in six‑well plates in PBS. 
Retinas were then dissected under a surgical microscope 
and washed 4‑5 times using filtered water to facilitate 
separation of the neural retinal layers from the blood 
vessels. Subsequently, retinas were incubated in 
0.1 M Tris buffer (pH 7.8, Sigma, T8193) containing 3% 
trypsin (Difco 1:250, Amresco LLC, 0458) at 37°C for 
90 min. Water washes were used to disintegrate the 
neuronal tissues and debris from the vascular network. 
The  retinal  vascular  network was  then flatmounted 
on a slide and stained with periodic acid solution 
(PAS, Sigma, 3951), Schiff’s reagent (Sigma, 3952016), 
and hematoxylin (Sigma, GHS316).
Statistical Analysis
Values were expressed as mean ± SEM. Data were 
analyzed using Student’s t‑test. Statistical significance 
was considered at P < 0.05. Unless specified otherwise, n 
indicates the number of independent animal experiments.
RESULTS
Diabetic Retinal Leukocyte Accumulation and 
ICAM‑1 Expression
Leukocyte accumulation is a key component of 
experimental diabetic retinopathy (DR).[20] To enumerate 
the firmly adhering leukocytes, histological flatmounts 
from the retinas of normal and diabetic animals were 
prepared [Figure 1a]. Retinal arteries and veins of 
diabetic animals showed more pronounced leukocyte 
accumulation compared to those of normal controls 
[Figure 1b].
Next, we stained for the leukocyte activation 
marker CD18, a ligand for endothelial ICAM‑1. Firmly 
adhering leukocytes in the retinal vessels expressed 
Figure 1. Leukocyte accumulation and ICAM‑1 expression in the diabetic retina. (a) Leukocyte adhesion in retinal vessels of 
normal and diabetic rats. (b) Quantification of leukocytes in retinal arteries and veins (n = 6). (c) Immunohistochemistry of firmly 
adhering leukocytes (red) for CD18, a ligand for the endothelial ICAM‑1. (d) Western blot analysis for ICAM‑1 using retinal extracts 
of normal and diabetic rats (three weeks after STZ injection). (e) Western blotting results showing higher ICAM‑1 expression in 
retinal tissues of diabetic rats (n = 8 animals) than in those of normal controls (n = 7 animals).
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CD18 [Figure 1c]. Western blotting was performed to 
quantify endothelial ICAM‑1 expression in the diabetic 
retinas [Figure 1d]. ICAM‑1 protein levels in the retinal 
tissues  of  three‑week diabetic  rats were  significantly 
higher than those in normal rats [Figure 1e]
Characterization of Molecular Imaging Probes
The number of ligands on the surface of the imaging 
probes was quantified following our previously 
established protocol.[10,12] PE‑conjugated anti‑murine 
IgG and isotype‑matched control IgG were used to 
stain the antibodies on the imaging probes [Figure 2a]. 
Fluorescence intensities of the probes and calibration 
microspheres with known site densities of PE‑conjugated 
IgG were measured via flow cytometry.[13] A calibration 
curve was generated (R² =0.99) and used to determine the 
average number of α‑ICAM‑1 antibodies (n = 2.6 × 103) 
on the probe surface.
To examine the specificity and adhesion properties of 
our imaging probes under controlled flow conditions, we 
performed in vitro flow studies following our previously 
described protocols [Figure 2b].[18] Recombinant ICAM‑1 
protein was immobilized on the inner chamber surfaces. 
Subsequently, live video microscopy of the flow of the 
imaging probes through the chambers was recorded 
for 6 min, and numbers of adhering probes were 
quantified  every  30  s  [Figure 2c]. At 6 min after the 
start  of  imaging,  the  ICAM‑1‑coated flow  chambers 
showed significantly more pronounced accumulation of 
α‑ICAM‑1 probes than those of IgG‑conjugated control 
probes under the same conditions (P < 0.01), thereby 
demonstrating the specificity of the accumulated probes 
for ICAM‑1 [Figure 2d].
Molecular Imaging of Endothelial Injury in 
Diabetic Animals
To monitor endothelial injury in vivo, we used our 
new molecular imaging approach[10,12] designed for 
early diagnosis[12] and use in mechanistic studies to 
monitor the retinal microvessels.[15] Imaging probes 
were generated by conjugating the binding ligands 
of endothelial ICAM‑1 onto the surfaces of injectable 
fluorescent microspheres. These α‑ICAM‑1 or control 
probes were then injected into the bloodstreams of 
normal and diabetic animals. Accumulation of the 
firmly  adhering probes in vivo was visualized using 
SLO [Figure 3a]. Firmly adhering probes were visible 
as bright dots in the fundus images of the examined 
eyes [Figure 3b]. The number of α‑ICAM‑1 and 
IgG‑conjugated probes, which were used as negative 
controls, did not differ  significantly between diabetic 
and normal rats. However, a significantly higher 
number of α‑ICAM‑1 probes adhered to the retinal 
vessels of the diabetic rats than those in normal 
controls [Figure 3c]. A significant difference in adhesion 
of α‑ICAM‑1 probes was also observed between normal 
Figure 2. Characterization of the molecular imaging probes. (a) Flow cytometry analysis of non‑fluorescent α‑ICAM‑1 probes 
labeled with FITC‑conjugated mAb or isotype control and IgG‑conjugated probes with isotype control. (b) Schematic of the 
microfluidic experiments. Recombinant ICAM‑1 was immobilized, and probe interactions were visualized via live microscopy. 
(c) Representative video micrographs showing the interactions of the imaging probes with the immobilized ICAM‑1 at 
2 dynes/cm2. (d) Quantification of probe adhesion illustrates specific adhesion of probes to immobilized ICAM‑1.
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Imaging probe accumulation precedes structural injury in 
the retina
A key morphological feature of the diabetic retina is 
the formation of acellular, nonperfused capillaries,[21]
which is caused by microenvironmental damage to the 
endothelium, matrix, and pericyte.[21] Early diagnosis is 
required for therapeutically effective treatment before 
irreversible structural damage occurs. To investigate 
these structural changes, we performed trypsin digestion 
of the retinas of normal and diabetic animals. Retinas 
of normal rats showed patent capillaries containing 
endothelial cells and surrounding pericytes [Figure 5a]. 
Similarly, no evident structural pathologies, such as 
pericyte loss or acellular capillaries, were observed in 
the three‑week diabetic animals [Figure 5b]. In contrast, 
obliterated acellular capillaries, a classic sign of DR 
pathology, was frequently observed in long‑term diabetic 
animals [Figure 5c]. Thus, molecular imaging can detect 
endothelial injury in the diabetic retina at an early time 
point when no visible structural pathology is evident.
DISCUSSION
The progression from physiological to pathological 
conditions in DR involves a sequence of events 
initiated by molecular changes, followed by cellular 
and six‑week diabetic animals injected with α‑ICAM‑1 
probes [Figure 3d]. To examine the effect of probe size 
on binding efficacy, we used probes with 1‑ and 2‑μm 
diameters. In diabetic animals, the smaller probes had a 
higher binding ratio than the control probes [Figure 3e].
Ex vivo Visualization of Probe Accumulation 
in Retinal Micro Vessels
To verify the interaction of the imaging probes with 
the  retinal  endothelium, histological flatmounts were 
prepared and subsequently examined via epifluorescence 
microscopy [Figure 4a]. Consistent with our in vivo 
findings, retinal vessels of normal and diabetic animals 
showed no difference in the adhesion of IgG probes, 
which were used as negative controls. However, retinal 
microvessels of diabetic rats showed significantly more 
pronounced adhesion of the α‑ICAM‑1 probes compared 
to those of normal rats [Figure 4b].
Leukocytes constitutively express ICAM‑1, which was 
also targeted by the imaging probes in the diabetic retina. 
A fraction of the α‑ICAM‑1 imaging probes was firmly 
bound to adhering leukocytes [Figure 4c], consistent with 
our previous reports using a lipopolysaccharide‑induced 
model of acute inflammation.[10,12] The capability of 
molecular imaging to detect accumulated leukocytes 
could potentially be used for quantification of specific 
immune responses in the retina.
Figure 4. Ex-vivo evaluation of imaging probe accumulation. 
Retinal flatmounts were prepared from animals perfused 
with rhodamine‑ConA (red). Imaging probes that resisted 
perfusion are visible as green spots in fluorescence microscopy. 
(a) Representative retinal micrographs show probe adhesion in 
retinal vessels of normal and diabetic rats. (b) Quantification of 
α‑ICAM‑1 probe adhesion in retinal vessels (n = 6–8, **P < 0.01). 
(c)  Imaging probes bound  to firmly adhering  leukocytes  in 
retinal vessels. Micrograph shows rhodamine‑stained leukocytes 
(blue arrows) and α‑ICAM‑1 probes (green/yellow).
cb
a
Figure 3. In-vivo detection of endothelial injury using 
molecular imaging. (a) Schematic of our in vivo molecular 
imaging approach. (b) Representative SLO‑micrographs 
from the retinas of normal and diabetic animals. White dots 
represent firmly adhering probes. (c) In-vivo probe adhesion 
in normal and three‑week diabetic animals (n = 5, **P < 0.01). 
(d) Molecular imaging of retinal endothelial ICAM‑1 in 
6‑diabetic animals (n = 6, **P < 0.01). (e) Comparison between 
the binding of two differently sized α‑ICAM‑1 imaging 
probes (1 and 2 μm) in diabetic retinas (n = 5).
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responses eventually leading to structural damage. 
Clinically detectable structural changes, such as acellular 
capillaries, microaneurysms, or neovascularization, 
severely compromise disease prognosis. Therefore, 
detection of the early molecular changes in the retinal 
endothelium during diabetes onset is critical as it can 
ideally enable adequate treatment before irreversible 
structural damage occurs. An urgent need thus exists 
to identify biomarkers for early DR and to develop 
practical strategies for subclinical diagnosis.[3] However, 
retinal endothelial injury in diabetic patients[3] cannot be 
visualized using existing techniques, which only detect 
structural damage.
To address the unmet need for an early diagnostic 
tool for DR, we developed an imaging technique 
measuring in vivo mono molecular interactions using 
custom‑designed molecular imaging probes.[10,11,12,15] Our 
approach is based on the principle that one of the earliest 
responses of the retina to hyperglycemia is immune 
cell accumulation in the retinal vasculature. Leukocyte 
accumulation is caused by the expression of adhesion 
molecules, such as ICAM‑1, in the retinal endothelium 
of diabetic animals. Higher ICAM‑1 expression has been 
observed in the eyes of diabetic individuals, making 
ICAM‑1 a clinically relevant target.[7] To visualize 
ICAM‑1, we developed imaging probes that mimic early 
leukocyte endothelial interactions and which can be 
detected using fluorescent signals [Figure 6].
Our current approach is ideal for visualization of 
retinal endothelial molecules, since the structure of 
the eye provides a unique platform for light‑based 
molecular imaging. The high sensitivity and specificity 
of the molecular imaging probes make them highly 
suitable for the detection of low‑grade inflammation, as 
observed in DR.[10,11] Using this non‑invasive approach, 
we demonstrated elevated ICAM‑1 expression levels in 
the retinal vessels of T1D animals. This novel approach 
represents a great advancement that can be applied to 
humans.
Clinical use of this technique is feasible as the imaging 
probes can be constructed entirely from FDA‑approved 
components safe for human use, such as biodegradable 
polymers including poly(epsilon‑caprolactone) (PCL) 
and poly (D, L‑lactide‑co‑glycolide) (PLGA),[22,23] both 
of which are approved for clinical use in targeted drug 
delivery systems. The FDA‑approved dyes indocyanine 
green (ICG) and fluorescein[24] have established safety 
profiles  and  can  thus be utilized  as fluorophores  for 
encapsulation in the imaging probes.
We demonstrate that non‑invasive molecular 
imaging can distinguish between normal and diabetic 
retinas at an early time point when structural damage 
is not yet evident. In this study, ICAM‑1 was selected 
as the imaging target because it mediates leukocyte 
accumulation in the retina.[7,8] However, other endothelial 
surface molecules, such as growth factor receptors 
and glycocalyx components, can be targeted using the 
same principles. We recently demonstrated the in vivo 
upregulation of VEGFR‑2 in both the retinal microvessels 
of diabetic animals and human eyes.[14]
The high sensitivity and specificity of the molecular 
probes,[10] the quantitative nature of the detected 
signals,[11] and the automated processing[12] makes this 
technique a potentially powerful tool for monitoring 
early events in diabetic retinal microangiopathy that 
can meet the need for an early diagnostic tool for DR 
detection. Molecular imaging of retinal endothelial 
ICAM‑1 could provide an early warning signal before 
clinical symptoms develop, and effective treatments at 
this early stage could prevent disease progression.
Figure 6. Sensitive detection of endothelial injury by mimicking 
leukocyte function. Under normal conditions, leukocytes freely 
flow  in  the  bloodstream and do not  interact with healthy 
endothelia (upper left). Diabetic endothelia express ICAM‑1, 
which mediates firm leukocyte adhesion (upper right). Imaging 
probes that target endothelial ICAM‑1 apply this principle to 
detect early vascular changes in vivo. α‑ICAM‑1 probes that 
target endothelial ICAM‑1 show significantly higher interaction 
with diabetic endothelia (lower right) than in those of normal 
animals (lower left).
Figure 5. Early detection by molecular imaging precedes 
structural damage. Retinas of normal and diabetic animals 
were trypsin‑digested to visualize vascular changes in the 
diabetic  retina. PAS and hematoxylin‑stained flatmounts of 
trypsin‑digested normal retinas show patent retinal capillaries, 
which are comprised of endothelial cells and are surrounded 
by pericytes (a). At three weeks of diabetes, retinas of diabetic 
animals show no signs of structural damage (b). In contrast, 
long‑term diabetic animals (six months) display obliterated 
acellular capillaries (arrow) (c). Bar, 50 μm.
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